Abstract: The invention provides a method of forming a plurality of re-constitutable doses of at least one drug in a plurality of wells, the method including the steps of (i) placing a known amount of said drug in a suitable carrier to form a first composition having a known concentration (ii) placing at least two selected amounts of that first composition into individual wells and (iii) converting the first composition into a transportable form that can later be converted into a second composition having a known concentration and (iv) sealing the wells.

Abstract: A genetic trait predictor is generated by blending individual molecular estimates with estimates of at least one genetic value derived from quantitative trait measure. The individual molecular estimates may include molecular trait estimates or molecular trait variance. The individual molecular estimates may be determined by applying individual deoxyribonucleic acid (DNA) markers, DNA marker panels, specific parameter estimates and specific parameter variance thereof, and a genotype of a test sample. Quantitative trait measure may include estimated breeding data, raw trait data, and breed composition data. The genetic predictor is accurate and stable under a wide range of conditions and relatively immune to errors in parameter estimation.

Abstract: Provided herein are substituted pyrimidine and triazine derivatives, including bicyclic pyrimidine derivatives, their pharmaceutical compositions, their preparation, and their use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. In one embodiment, the pyrimidine and triazine derivatives are morpholino-pyrimidine, morpholino-triazine, pyridyl-pyrimidine, and pyridyl-triazine derivatives which are selective irreversible inhibitors of the p110? isoform of PI3K.

Abstract: The invention relates to the use of a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof to treat prodromal syndrome and in the manufacture of a medicament for the treatment of prodromal syndrome, and to a method of treatment of prodromal syndrome using a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof. It also relates to the use of a pharmaceutical composition comprising a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof, and at least one cholinergic agent and/or at least one non-cholinergic agent for the treatment of prodromal syndrome, and to a method of treatment of prodromal syndrome by administration of a such a pharmaceutical composition.

Abstract: The invention relates to the use of a functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof for the treatment of negative symptoms of schizophrenia. It also relates to adjunctive and simultaneous combination therapies for the treatment of negative symptoms of schizophrenia in which the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof and at least one neuroprotective agent, neuroleptic and/or atypical antipsychotic agent are administered adjunctively or simultaneously. The invention also provides methods of treatment of the negative symptoms of schizophrenia utilising such therapies and such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them.

Abstract: The invention relates to the use of a functional muscarinic M1/M4 receptor agonist such as the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof in for the treatment of cognitive impairment in schizophrenia and to combination therapies for the treatment of cognitive impairment in schizophrenia which the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof and at least one other neuroprotective agent and/or neuroleptic and/or atypical antipsyhcotic agent are administered adjunctively or simultaneously. The invention provides methods of treatment of cognitive impairment in schizophrenia utilising such therapies and such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them.

Abstract: This invention relates to an adhesive article comprising a pressure sensitive adhesive having a first and second surface and a lightweight paper adhered to the first surface. The article may also include a release liner. The adhesive articles may be directly applied in decorative or artistic projects without the need for an external glue. Those projects include the use of these papers in scrapbooks, decorations for wall boards, etc.

Abstract: The present invention provides a method for the preparation of pigment granules that are readily dispersible, robust, and have a reduced liability to dusting, preferably without the use of substantial quantities of binder, if any at all. The method comprises mixing at least one pigment selected from the group consisting of iron oxides, chromium oxides, cobalt blues, mixed metal oxides, carbon blacks and titanium oxides, with water to form a mixture having a dough-like consistency. The mixture is then extruded through at least one die to form extruded granules, thereby also compacting the mixture, which increases the strength of the granules. The extruded granules are then dried so that the final water content of the granules is less than substantially 5%.

Abstract: The present invention provides a method for the preparation of pigment granules that are readily dispersible, robust, and have a reduced liability to dusting, preferably without the use of substantial quantities of binder, if any at all. The method comprises mixing at least one pigment selected from the group consisting of iron oxides, chromium oxides, cobalt blues, mixed metal oxides, carbon blacks and titanium oxides, with water to form a mixture having a dough-like consistency. The mixture is then extruded through at least one die to form extruded granules, thereby also compacting the mixture, which increases the strength of the granules. The extruded granules are then dried so that the final water content of the granules is less than substantially 5%.

Abstract: This invention provides 29-desmethylrapamycin of Formula I: and a pharmaceutical composition thereof.

Abstract: The invention is directed to methods to assess connective tissue, especially bone, metabolism in disease or to monitor therapy, which method comprises assessing the levels of native free collagen-derived crosslinks in biological fluids, especially urine. The method can be enhanced by concomitantly determining the levels of an indicator of bone formation in biological fluids of the same individual and assessing the differences between the degradation marker and the formation indicator. Antibodies which are specifically immunoreactive with forms of crosslinks which occur free in biological fluids are also disclosed.

Abstract: Novel compounds of formula (I): ##STR1## wherein R.sup.1 is hydrogen or optionally protected hydroxy; R.sup.2 is alkoxy, optionally protected hydroxy, oxo or optionally O-substituted oximino; R.sup.3 is hydrogen, optionally protected hydroxy,or a group 4'-(.alpha.-L-oleandrosyl)-.alpha.-L-oleandrosyloxy or .alpha.-L-oleandrosyloxy wherein the terminal hydroxy group is optionally protected; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are the same or different and each is hydrogen or an organic radical; and R.sup.8 is an optionally substituted amino or imino group such as optionally O-substituted oxyimino, optionally N-substituted hydrazone, or optionally N-substituted semicarbazone; are useful in the treatment of helminthiasis in humans and animals.

Abstract: The invention is directed to methods to assess connective tissue, especially bone, metabolism in disease or to monitor therapy, which method comprises assessing the levels of native free collagen-derived crosslinks in biological fluids, especially urine. The method can be enhanced by concomitantly determining the levels of an indicator of bone formation in biological fluids of the same individual and assessing the differences between the degradation marker and the formation indicator. Antibodies which are specifically immunoreactive with forms of crosslinks which occur free in biological fluids are also disclosed.

Abstract: The invention is directed to methods to assess connective tissue, especially bone, metabolism in disease or to monitor therapy, which method comprises assessing the levels of native free collagen-derived crosslinks in biological fluids, especially urine. The method can be enhanced by concomitantly determining the levels of an indicator of bone formation in biological fluids of the same individual and assessing the differences between the degradation marker and the formation indicator. Antibodies which are specifically immunoreactive with forms of crosslinks which occur free in biological fluids are also disclosed.

Abstract: A process of preparing a solid herbicidal formulation containing a high concentration of a bipyridylium diquaternary salt, which comprises injecting a solution of the bipyridylium salt into a heated fluid bed of a particulate carrier, so that the bipyridylium salt is deposited onto the carrier.

Abstract: A process for the continuous melt thermoforming of thermoplastic polymers is disclosed. The process comprises extruding a flat web of molten polymer in a downward direction and directly over a series of mould cavities moving at a predetermined speed thereby sequentially covering the mould cavities. A vacuum is applied to the mould cavities and the web of molten polymer is brought into contact with the surface of the mould cavity, the mould defining the mould cavity being comprised of porous metal. The polymer is cooled and the resultant article is removed from the mould. The process is controlled so that the articles thermoformed in the process are of substantially uniform thickness. In embodiments the mould cavities are located on the periphery of a continuous belt or preferably a wheel. The process may be operated with polymers of low zero shear viscosity. The preferred polymers are polyamides, especially polyhexamethylene adipamide, of relative viscosity in the range 25 to 65.